Search research articles
Contact Us
Filters
Showing results (1201-1210 of 1,291) with videos related to
Page
of 130
Sort By:
Cancers
|
October 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
Eva-Maria Klein, Diana Tichy, Hans J Salwender, et al.
Haematologica
|
January 29, 2026
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial
Friedrich Stölzel, Matthias Stelljes, Dietrich Wilhelm Beelen, et al.
Bone Marrow Transplantation
|
May 6, 2018
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties
Peter Dreger, Mauricette Michallet, Paul Bosman, et al.
Blood Cancer Journal
|
January 8, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Marc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, et al.
American Journal of Hematology
|
May 26, 2022
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial
Dietrich W Beelen, Matthias Stelljes, Péter Reményi, et al.
Haematologica
|
January 2, 2008
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
Henk M Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveld, et al.
Haematologica
|
September 3, 2013
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial
Christof Scheid, Pieter Sonneveld, Ingo G H Schmidt-Wolf, et al.
Bone Marrow Transplantation
|
March 28, 2023
The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT
Olivier Tournilhac, Michel van Gelder, Dirk-Jan Eikema, et al.
Blood
|
May 10, 2024
Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?
Christof Scheid, Diderik-Jan Eikema, Michel van Gelder, et al.
Journal of Hepatology
|
September 5, 2022
Non-invasive tests for clinically significant portal hypertension after HCV cure
Georg Semmler, Sabela Lens, Elias L Meyer, et al.
Page
of 130
Search research articles
Search
Showing results (1201-1210 of 1,291) with videos related to
Sort By:
Page
of 130
Cancers
|
October 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
Eva-Maria Klein, Diana Tichy, Hans J Salwender, et al.
Haematologica
|
January 29, 2026
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial
Friedrich Stölzel, Matthias Stelljes, Dietrich Wilhelm Beelen, et al.
Bone Marrow Transplantation
|
May 6, 2018
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties
Peter Dreger, Mauricette Michallet, Paul Bosman, et al.
Blood Cancer Journal
|
January 8, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Marc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, et al.
American Journal of Hematology
|
May 26, 2022
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial
Dietrich W Beelen, Matthias Stelljes, Péter Reményi, et al.
Haematologica
|
January 2, 2008
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
Henk M Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveld, et al.
Haematologica
|
September 3, 2013
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial
Christof Scheid, Pieter Sonneveld, Ingo G H Schmidt-Wolf, et al.
Bone Marrow Transplantation
|
March 28, 2023
The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT
Olivier Tournilhac, Michel van Gelder, Dirk-Jan Eikema, et al.
Blood
|
May 10, 2024
Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?
Christof Scheid, Diderik-Jan Eikema, Michel van Gelder, et al.
Journal of Hepatology
|
September 5, 2022
Non-invasive tests for clinically significant portal hypertension after HCV cure
Georg Semmler, Sabela Lens, Elias L Meyer, et al.
Page
of 130